Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.

Cognition disorders Huntington’s disease Motor disorders Neurodegeneration Polyglutamine

Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 10 04 2018
accepted: 07 06 2018
revised: 06 06 2018
pubmed: 30 6 2018
medline: 7 6 2019
entrez: 30 6 2018
Statut: ppublish

Résumé

Huntington's disease (HD) is a fatal neurodegenerative disease caused by mutant HTT gene expansions of CAG triplet repeat numbers that are inherited in an autosomal dominant manner. HD patients display multiple clinical features that are correlated with HTT CAG repeat numbers that include age of disease onset, motor dysfunction, cognitive deficits, compromised daily living capacity, and brain neurodegeneration. It is important to understand the significant relationships of the multiple HD clinical deficits correlated with the number of mutant HTT CAG expansions that are the genetic basis for HD disabilities. Therefore, this review highlights the significant correlations of the HD clinical features of age of onset, motor and cognitive disabilities, decline in living capabilities, weight loss, risk of death, and brain neurodegeneration with respect to their associations with CAG repeat lengths of the HTT gene. Quantitative HTT gene expression patterns analyzed in normal adult human brain regions demonstrated its distribution in areas known to undergo neurodegeneration in HD, as well as in other brain regions. Future investigation of the relationships of the spectrum of clinical HD features with mutant HTT molecular mechanisms will be important to gain understanding of how mutant CAG expansions of the HTT gene result in the devastating disabilities of HD patients.

Identifiants

pubmed: 29956026
doi: 10.1007/s00415-018-8940-6
pii: 10.1007/s00415-018-8940-6
doi:

Substances chimiques

HTT protein, human 0
Huntingtin Protein 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

551-564

Subventions

Organisme : National Institutes of Health
ID : T32DA07315

Références

J Med Genet. 1999 Feb;36(2):172-3
pubmed: 10051023
Exp Neurol. 1999 May;157(1):1-18
pubmed: 10222105
J Neurol. 1999 Nov;246(11):1090-3
pubmed: 10631644
Neurology. 2000 Jan 25;54(2):452-8
pubmed: 10668713
Clin Genet. 2002 Jun;61(6):437-42
pubmed: 12121351
Neurobiol Dis. 2002 Aug;10(3):378-86
pubmed: 12270698
Exp Brain Res. 2003 Feb;148(3):308-19
pubmed: 12541142
Brain. 2003 Apr;126(Pt 4):946-55
pubmed: 12615650
Mov Disord. 2004 Jan;19(1):68-75
pubmed: 14743363
Neuropathol Appl Neurobiol. 1992 Dec;18(6):539-47
pubmed: 1488086
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3498-503
pubmed: 14993615
Neurology. 2005 Sep 27;65(6):941-3
pubmed: 16186542
Neurology. 2006 Apr 11;66(7):1016-20
pubmed: 16606912
Arch Neurol. 2006 Jun;63(6):883-90
pubmed: 16769871
Neurology. 2006 Jun 13;66(11):1638-43
pubmed: 16769933
J Med Genet. 2007 Jan;44(1):44-50
pubmed: 17018562
Ann Hum Genet. 2007 May;71(Pt 3):295-301
pubmed: 17181545
Neuroreport. 2007 Jan 8;18(1):73-6
pubmed: 17259864
PLoS Genet. 2007 May 11;3(5):e82
pubmed: 17500595
J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):130-5
pubmed: 17615168
Eur J Epidemiol. 2007;22(8):523-6
pubmed: 17653603
J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):874-80
pubmed: 18096682
Mov Disord. 2008 Jul 15;23(9):1223-7
pubmed: 18512767
J Neurol Sci. 2009 Jan 15;276(1-2):159-62
pubmed: 18977004
Neurology. 2008 Nov 4;71(19):1506-13
pubmed: 18981372
Brain. 2010 Apr;133(Pt 4):1094-110
pubmed: 20375136
Mov Disord. 2010 Jul 30;25(10):1444-50
pubmed: 20629137
Physiol Rev. 2010 Jul;90(3):905-81
pubmed: 20664076
J Nucl Med. 2010 Sep;51(9):1413-7
pubmed: 20720046
Lancet Neurol. 2011 Jan;10(1):83-98
pubmed: 21163446
Hum Brain Mapp. 2011 Feb;32(2):258-70
pubmed: 21229614
Mov Disord. 2011 Aug 1;26(9):1691-7
pubmed: 21611979
J Neurol Sci. 2011 Aug 15;307(1-2):60-8
pubmed: 21624624
Int Rev Neurobiol. 2011;98:373-418
pubmed: 21907095
Biol Psychiatry. 2012 May 1;71(9):822-8
pubmed: 21907324
Mov Disord. 2011 Dec;26(14):2544-51
pubmed: 21932302
Mov Disord. 2012 Feb;27(2):272-6
pubmed: 22173986
Neurology. 2012 Mar 6;78(10):690-5
pubmed: 22323755
Can J Neurol Sci. 2012 Jan;39(1):48-51
pubmed: 22384495
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1030-6
pubmed: 22526956
J Biol Chem. 2012 Jun 22;287(26):21599-614
pubmed: 22556411
Cell Cycle. 2012 May 15;11(10):2006-21
pubmed: 22580459
Curr Opin Neurol. 2012 Aug;25(4):491-8
pubmed: 22772878
Neuron. 2012 Jul 12;75(1):41-57
pubmed: 22794259
Neuroimage. 2012 Oct 15;63(1):517-24
pubmed: 22796981
Neurology. 2012 Oct 16;79(16):1708-15
pubmed: 23035064
Lancet Neurol. 2013 Jul;12(7):637-49
pubmed: 23664844
Trends Biochem Sci. 2013 Aug;38(8):378-85
pubmed: 23768628
PLoS One. 2013 Sep 03;8(9):e73280
pubmed: 24019913
Cortex. 2014 Mar;52:98-112
pubmed: 24405816
Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1210-20
pubmed: 24566949
Brain Pathol. 2014 Apr;24(3):247-60
pubmed: 24779419
J Clin Neurosci. 2014 Oct;21(10):1773-8
pubmed: 25017428
J Huntingtons Dis. 2013;2(4):477-89
pubmed: 25062732
Brain Connect. 2014 Sep;4(7):535-46
pubmed: 25072408
Mov Disord. 2014 Sep;29(10):1281-8
pubmed: 25209258
Curr Top Behav Neurosci. 2015;22:33-80
pubmed: 25300927
JAMA Neurol. 2014 Dec;71(12):1520-8
pubmed: 25322077
Brain. 2015 Aug;138(Pt 8):2332-46
pubmed: 26059655
Am J Hum Genet. 2016 Feb 4;98(2):287-98
pubmed: 26849111
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1171-82
pubmed: 26899245
Neuron. 2016 Mar 2;89(5):910-26
pubmed: 26938440
Nat Rev Dis Primers. 2015 Apr 23;1:15005
pubmed: 27188817
J Int Neuropsychol Soc. 2016 Jul;22(6):595-608
pubmed: 27211109
Hum Brain Mapp. 2016 Dec;37(12):4615-4628
pubmed: 27477323
Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):null
pubmed: 27940602
Cerebellum. 2017 Dec;16(5-6):923-928
pubmed: 28528357
Hum Brain Mapp. 2017 Oct;38(10):5035-5050
pubmed: 28657159
Sci Rep. 2017 Jul 12;7(1):5216
pubmed: 28701700
Ann Neurol. 2017 Sep;82(3):479-483
pubmed: 28779551
J Neuropathol Exp Neurol. 1985 Nov;44(6):559-77
pubmed: 2932539
J Med Genet. 1994 Nov;31(11):872-4
pubmed: 7853373
Ann Neurol. 1994 Oct;36(4):630-5
pubmed: 7944295
Nat Genet. 1993 Aug;4(4):398-403
pubmed: 8401589
Cell. 1993 Mar 26;72(6):971-83
pubmed: 8458085
Neurology. 1996 Feb;46(2):527-31
pubmed: 8614526
Neurology. 1997 Feb;48(2):394-9
pubmed: 9040728
Ann Neurol. 1997 May;41(5):689-92
pubmed: 9153534
Brain. 1997 Sep;120 ( Pt 9):1569-78
pubmed: 9313640
J Neuropathol Exp Neurol. 1998 May;57(5):369-84
pubmed: 9596408

Auteurs

Sonia Podvin (S)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, MC0719, La Jolla, San Diego, CA, 92093-0719, USA.

Holly T Reardon (HT)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, MC0719, La Jolla, San Diego, CA, 92093-0719, USA.

Katrina Yin (K)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, MC0719, La Jolla, San Diego, CA, 92093-0719, USA.

Charles Mosier (C)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, MC0719, La Jolla, San Diego, CA, 92093-0719, USA.

Vivian Hook (V)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, MC0719, La Jolla, San Diego, CA, 92093-0719, USA. vhook@ucsd.edu.
Department of Neurosciences, University of California, 9500 Gilman Drive, MC0719, La Jolla, San Diego, CA, 92093-0719, USA. vhook@ucsd.edu.
Department of Pharmacology, University of California, 9500 Gilman Drive, MC0719, La Jolla, San Diego, CA, 92093-0719, USA. vhook@ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH